-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Investor Hub
Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.
Latest investor presentation
Latest quarterly earnings
Latest clinical presentation
Latest publications, posters & presentations
Annual report
NASDAQ:NVAX
Latest press releasesEvents & presentationReports & financialsSEC filingsStock details & analyst coverage
SEC
Access filings by selecting the date range and type using the drop-down menus.
Why invest with us
We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.
I came out of retirement to join the fight.
Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine
Get notifications for investor updates
Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.
Investor inquiries
Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at [email protected]
Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.
